Holen Sie sich die Stockscreener-App
110.64
4.74%
-5.51
Handel nachbörslich:
110.64
Cidara Therapeutics Inc Aktie (CDTX) Neueste Nachrichten
Cidara Therapeutics Inc.’s volatility index tracking explained2025 AllTime Highs & High Conviction Trade Alerts - newser.com
Will Cidara Therapeutics Inc. stock deliver long term returnsWeekly Trade Analysis & AI Enhanced Market Trend Forecasts - newser.com
Analyzing drawdowns of Cidara Therapeutics Inc. with statistical toolsExit Point & Weekly Momentum Picks - newser.com
Can Cidara Therapeutics Inc. (20D0) stock reach $200 price targetJuly 2025 Setups & Detailed Earnings Play Strategies - newser.com
Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025 - MarketScreener
How Cidara Therapeutics Inc. stock benefits from strong dollarPortfolio Return Summary & Fast Gaining Stock Strategy Reports - newser.com
Can machine learning forecast Cidara Therapeutics Inc. recoveryWeekly Trade Report & Verified Stock Trade Ideas - newser.com
Cidara to present phase 2 data on influenza drug at ID Week 2025 - Investing.com
How Cidara Therapeutics Inc. stock compares to growth peers2025 EndofYear Setup & Daily Risk Controlled Trade Plans - newser.com
Cidara Therapeutics to Present Late-Breaking Phase 2 Data on CD388 for Influenza at ID Week 2025 - Quiver Quantitative
Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025 - The Manila Times
Can you recover from losses in Cidara Therapeutics Inc.Weekly Profit Summary & Stepwise Trade Execution Plans - newser.com
What hedge fund moves indicate for Cidara Therapeutics Inc. (20D0) stockJuly 2025 EndofMonth & Low Drawdown Momentum Ideas - newser.com
Using Ichimoku Cloud for Cidara Therapeutics Inc. technicals2025 AllTime Highs & Consistent Return Strategy Ideas - newser.com
What institutional flow reveals about Cidara Therapeutics Inc.Quarterly Trade Report & Verified Momentum Stock Alerts - newser.com
Cidara Therapeutics (NASDAQ:CDTX) Shares Gap Up on Analyst Upgrade - MarketBeat
Cidara Therapeutics (NASDAQ:CDTX) Now Covered by JPMorgan Chase & Co. - MarketBeat
JP Morgan Initiates Coverage on CDTX with Overweight Rating | CD - GuruFocus
Cidara Therapeutics (CDTX) Is Up 10.8% After FDA Grants Breakthrough Therapy Designation to CD388 - Sahm
WBB Securities Issues Positive Forecast for Cidara Therapeutics (NASDAQ:CDTX) Stock Price - MarketBeat
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza - sharewise.com
Cidara Therapeutics Analyst Says Lead Influenza Candidate Is 'Strategically Attractive' - Benzinga
Why Cidara Therapeutics (CDTX) Is Up 12.4% After Breakthrough Therapy Status for Novel Flu Drug CD388 - Yahoo Finance
Cidara Therapeutics (NASDAQ:CDTX) Hits New 12-Month High Following Analyst Upgrade - MarketBeat
Cidara Therapeutics (NASDAQ:CDTX) Price Target Raised to $150.00 - MarketBeat
Cidara Therapeutics Surges Ahead of ESWI 2025 Presentation and JP Morgan Coverage - Benzinga
Cidara Therapeutics stock price target raised to $150 at H.C. Wainwright - Investing.com Canada
JP Morgan Initiates Coverage of Cidara Therapeutics (CDTX) with Overweight Recommendation - Nasdaq
How to build a dashboard for Cidara Therapeutics Inc. stockWeekly Risk Summary & AI Enhanced Trading Signals - newser.com
JPMorgan Initiates Coverage on Cidara Therapeutics With Overweight Rating, $200 Price Target - MarketScreener
Forecasting Cidara Therapeutics Inc. price range with options data2025 Volatility Report & Stepwise Swing Trade Plans - newser.com
Biotech And Healthcare Stocks Hit 52-Week Highs: Is The Momentum Sustainable? - Nasdaq
Why Cidara Therapeutics Inc. stock could be next big winnerQuarterly Profit Summary & Long Hold Capital Preservation Tips - newser.com
Cidara Therapeutics' (CDTX) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Why Cidara Therapeutics Stock Crushed It Today - sharewise.com
HC Wainwright & Co. Maintains Cidara Therapeutics (CDTX) Buy Recommendation - Nasdaq
CDTX Surges on FDA's Breakthrough Therapy Designation - GuruFocus
Cidara Therapeutics Surge: Time to Dive In? - StocksToTrade
FDA grants breakthrough therapy status to Cidara’s influenza drug By Investing.com - Investing.com Nigeria
CDTX Analyst Rating Update: WBB Securities Raises Price Target | - GuruFocus
Cidara Therapeutics stock hits 52-week high at 106.71 USD By Investing.com - Investing.com Nigeria
CDTX Achieves New Heights: What’s Next? - timothysykes.com
Cidara Therapeutics Granted FDA Breakthrough Therapy Designation For Flu-Preventing Antiviral - Stocktwits
Cidara wins FDA “Breakthrough” status for CD388 - The Pharma Letter
HC Wainwright Maintains Buy Rating on CDTX, Raises Price Target - GuruFocus
HC Wainwright Raises Cidara Therapeutics' Price Target to $150 From $110, Buy Rating Kept - MarketScreener
Cidara Therapeutics stock hits 52-week high at 106.71 USD - Investing.com India
Cidara Therapeutics (CDTX) Gains FDA Breakthrough Designation fo - GuruFocus
Cidara Therapeutics Receives FDA Breakthrough Therapy Designation for CD388 as Prophylactic Against Influenza A and B - Quiver Quantitative
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):